Sheila Frame | Vice President And Head Of Biopharmaceuticals
Sandoz Pharmaceutical Inc

Sheila Frame, Vice President & Head Sandoz Biopharmaceuticals, North America, is responsible for the development and commercialization of the biosimilar medicines portfolio in the US and Canada. Sheila has more than 20 years of pharmaceutical experience and serves as a member of the Sandoz US Executive Committee. A seasoned industry leader, Sheila has developed a knack for both long-term visionary business strategy as well as short-term operational expertise in the specialty businesses of immunology, immuno-oncology, and epilepsy.  Prior to joining Sandoz, Ms. Frame held the role of Worldwide General Manager for the Immunoscience business at Bristol Myers Squibb (BMS), a role which encompasses responsibility for the commercialization of Orencia® for the treatment of RA with worldwide sales of over $2 billion USD, as well as the commercial development of BMS’s important pipeline assets in the therapeutic area.